(Total Views: 565)
Posted On: 02/12/2024 7:51:31 PM
Post# of 148899
From seemingly-harmless,
“gilead liver disease purchase
https://finance.yahoo.com/news/drugmaker-gile...49.html”
From the web…primary biliary cholangitis - PBC is an autoimmune disorder. The immune system attacks the bile ducts, but the trigger for this attack is so far unidentified. Alcohol and diet are not thought to play significant roles in the development of the disease.
Here’s a very recent paper about seladelpar.
https://pubmed.ncbi.nlm.nih.gov/37904314/
“The primary analysis was for safety and the secondary efficacy analysis examined biochemical markers of cholestasis and liver injury. The study was terminated early due to the unexpected histological findings in a concurrent study for non-alcoholic steatohepatitis, which were subsequently found to predate treatment. Safety and efficacy data were analysed through 2 years.”
Sounds like it’s a potential immunomodulator, but I can’t speak to the pathways. The 4B price tag caught my interest.
“gilead liver disease purchase
https://finance.yahoo.com/news/drugmaker-gile...49.html”
From the web…primary biliary cholangitis - PBC is an autoimmune disorder. The immune system attacks the bile ducts, but the trigger for this attack is so far unidentified. Alcohol and diet are not thought to play significant roles in the development of the disease.
Here’s a very recent paper about seladelpar.
https://pubmed.ncbi.nlm.nih.gov/37904314/
“The primary analysis was for safety and the secondary efficacy analysis examined biochemical markers of cholestasis and liver injury. The study was terminated early due to the unexpected histological findings in a concurrent study for non-alcoholic steatohepatitis, which were subsequently found to predate treatment. Safety and efficacy data were analysed through 2 years.”
Sounds like it’s a potential immunomodulator, but I can’t speak to the pathways. The 4B price tag caught my interest.
(2)
(0)Scroll down for more posts ▼
